Life under the name Barinthus Biotherapeutics (Nasdaq: BRNS) has not started well for the UK company formerly known as Vaccitech.
The Oxford-based biopharma changed its name last year to reflect the company’s new focus on developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.
"While we didn’t observe a significant improvement from VTP-200 in the overall pooled results, we did observe positive trends in the highest dose cohorts"Last week, Barinthus announced top-line final data from the APOLLO trial, a completed randomized, placebo-controlled Phase Ib/II dose-ranging study of VTP-200 in women with low-grade cervical lesions associated with persistent high-risk human papillomavirus (hrHPV infection).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze